HCC
MCID: HPT023
MIFTS: 100

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 56 12 74 58 73 36 29 54 6 15 37 17
Liver Cancer 56 12 73 42 15
Primary Liver Cancer 12 52 15
Liver Neoplasms 74 43 71
Hepatoma 56 12 73
Hcc 56 58 73
Rare Tumor of Liver and Intrahepatic Biliary Tract 52 58
Primary Malignant Neoplasm of Liver 12 71
Malignant Neoplasm of Liver 12 71
Hepatoblastoma, Somatic 56 13
Cancer, Hepatocellular 56 39
Liver Cell Carcinoma 56 73
Hepatic Cancer 12 54
Hepatoblastoma 58 71
Lcc 56 73
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Hepatocellular Carcinoma, Childhood Type, Somatic 56
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 71
Resectable Malignant Neoplasm of the Liver 12
Childhood-Onset Hepatocellular Carcinoma 58
Adult Primary Hepatocellular Carcinoma 71
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Pediatric Hepatocellular Carcinoma 58
Hepatocellular Carcinoma, Somatic 56
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 52
Malignant Hepatobiliary Neoplasm 71
Hepatocellular Cancer, Somatic 56
Adult Hepatocellular Carcinoma 58
Rare Tumor of Liver and Ibt 58
Primary Tumor of the Liver 52
Liver Cell Carcinoma; Lcc 56
Carcinoma, Hepatocellular 43
Malignant Tumor of Liver 12
Primary Cancer of Liver 52
Primary Liver Carcinoma 52
Hepatocellular Cancer 73
Neoplasm of the Liver 6
Childhood-Onset Hcc 58
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 71
Liver Neoplasm 17
Pediatric Hcc 58
Adult Hcc 58
Hepatomas 15

Characteristics:

Orphanet epidemiological data:

58
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;
adult hepatocellular carcinoma
Inheritance: Not applicable;
pediatric hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adolescent,Childhood; Age of death: adolescent,adult,early childhood,late childhood,young Adult;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

31
hepatocellular carcinoma:
Inheritance autosomal dominant inheritance somatic mutation heterogeneous


Classifications:

Orphanet: 58  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to colorectal cancer and gastric cancer, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Pravastatin and Tegafur have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and lung, and related phenotypes are hepatomegaly and portal hypertension

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes and located in the liver.

OMIM : 56 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

KEGG : 36 Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. It has been shown that, after HBV/HCV infection and alcohol or aflatoxin B1 exposure, genetic and epigenetic changes occur. The recurrent mutated genes were found to be highly enriched in multiple key driver signaling processes, including telomere maintenance, TP53, cell cycle regulation, the Wnt/beta-catenin pathway (CTNNB1 and AXIN1), the phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Recent studies using whole-exome sequencing have revealed recurrent mutations in new driver genes involved in the chromatin remodelling (ARID1A and ARID2) and the oxidative stress (NFE2L2) pathways.

UniProtKB/Swiss-Prot : 73 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 74 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1634)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer 35.3 TP53 TERT PIK3CA PDGFRL NRAS NFE2L2
2 gastric cancer 35.2 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
3 breast cancer 35.0 TP53 TERT PIK3CA NRAS MIR34A MIR221
4 lung cancer 34.4 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
5 prostate cancer 34.4 TP53 TERT PIK3CA NFE2L2 MIR34A MIR221
6 lung cancer susceptibility 3 34.4 TP53 TERT PIK3CA NRAS NFE2L2 MIR21
7 cholangiocarcinoma 34.4 TP53 TERT PIK3CA MIR21 MET KRAS
8 non-alcoholic fatty liver disease 34.3 MIR34A MIR21 MIR17 MIR122
9 glioblastoma multiforme 34.3 TP53 TERT PIK3CA NRAS MIR34A MIR221
10 pancreatic cancer 34.2 TP53 TERT PIK3CA MIR34A MIR221 MIR21
11 melanoma 34.2 TP53 TERT PIK3CA NRAS MIR34A MIR221
12 ovarian cancer 34.0 TP53 TERT PIK3CA MIR34A MIR221 MIR21
13 esophageal cancer 34.0 TP53 TERT PIK3CA MIR34A MIR21 KRAS
14 neuroblastoma 33.9 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
15 leukemia, acute myeloid 33.9 TP53 TERT NRAS MIR34A MIR221 MIR21
16 renal cell carcinoma, nonpapillary 33.9 TP53 PIK3CA NRAS MIR34A MIR221 MIR21
17 bladder cancer 33.8 TP53 TERT PIK3CA NRAS MIR34A MIR221
18 pancreatic adenocarcinoma 33.8 TP53 TERT PIK3CA MIR221 MIR21 MET
19 adenocarcinoma 33.8 TP53 PIK3CA MET KRAS HRAS FGFR1
20 hepatitis b 33.6 TP53 PIK3CA MIR21 MIR17
21 intrahepatic cholangiocarcinoma 33.6 TP53 KRAS CTNNB1 APC
22 gastric adenocarcinoma 33.5 TP53 TERT PIK3CA NRAS MET KRAS
23 adenoma 33.5 TP53 PIK3CA KRAS CTNNB1 APC
24 cervical cancer 33.5 TP53 TERT PIK3CA NFE2L2 MIR34A MIR21
25 medulloblastoma 33.4 TP53 TERT PIK3CA NRAS MIR34A MIR17
26 hepatoblastoma 33.4 TP53 MIR21 MET CTNNB1 APC
27 endometrial cancer 33.4 TP53 TERT PIK3CA NRAS MIR34A KRAS
28 myeloma, multiple 33.4 TP53 NRAS MIR21 MIR17 MET KRAS
29 nasopharyngeal carcinoma 33.4 TP53 TERT PIK3CA NRAS MIR21 MIR17
30 lymphoma, non-hodgkin, familial 33.3 TP53 PIK3CA NRAS MIR34A MIR21 MIR17
31 sarcoma 33.2 TP53 PIK3CA NRAS MET KRAS HRAS
32 glioma 33.1 TP53 PIK3CA MIR34A MIR221 MIR21 MIR17
33 familial adenomatous polyposis 33.1 TP53 KRAS HRAS CTNNB1 AXIN1 APC
34 leukemia, chronic lymphocytic 33.0 TP53 NRAS MIR34A MIR221 MIR21 MIR17
35 lymphoma 33.0 TP53 PIK3CA NRAS MET FGFR1 CASP8
36 kidney cancer 33.0 TP53 PIK3CA NFE2L2 MIR21 MIR17 MIR122
37 gallbladder cancer 32.9 TP53 TERT PIK3CA KRAS CTNNB1 APC
38 thyroid carcinoma 32.9 TP53 PIK3CA NRAS HRAS CTNNB1
39 squamous cell carcinoma 32.9 TP53 PIK3CA NFE2L2 HRAS CTNNB1
40 colon adenocarcinoma 32.8 TP53 PIK3CA MIR21 KRAS CTNNB1 CASP8
41 bile duct cancer 32.8 TP53 MIR17 MET KRAS HRAS CTNNB1
42 bladder urothelial carcinoma 32.8 TP53 TERT PIK3CA NRAS NFE2L2 KRAS
43 leukemia 32.8 TP53 TERT NRAS KRAS HRAS FGFR1
44 acute promyelocytic leukemia 32.7 TERT NRAS MIR221 KRAS HRAS CASP8
45 brain cancer 32.7 TP53 TERT PIK3CA NRAS MIR17 HRAS
46 glioma susceptibility 1 32.7 TP53 PIK3CA NRAS MIR34A MIR221 MIR21
47 colorectal adenocarcinoma 32.7 TP53 KRAS HRAS CTNNB1 APC
48 myelodysplastic syndrome 32.6 TP53 TERT NRAS MIR34A KRAS HRAS
49 oral squamous cell carcinoma 32.6 TP53 MIR34A MIR221 MIR21 MIR17 MIR122
50 pancreatic ductal adenocarcinoma 32.5 TP53 MIR221 MIR21 KRAS HRAS CTNNB1

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Human phenotypes related to Hepatocellular Carcinoma:

58 31 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002240
2 portal hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0001409
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002027
4 hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002904
5 hypoalbuminemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003073
6 type ii diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0005978
7 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
8 abnormality of the rectum 58 31 frequent (33%) Frequent (79-30%) HP:0002034
9 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
10 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
11 esophageal varix 58 31 frequent (33%) Frequent (79-30%) HP:0002040
12 venous insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0005293
13 abdominal distention 58 31 frequent (33%) Frequent (79-30%) HP:0003270
14 epigastric pain 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0410019
15 hypokalemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002900
16 fatigue 58 31 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0012378
17 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
18 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
19 hypoglycemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001943
20 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
21 anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001903
22 neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0002664
23 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
24 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
25 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
26 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
27 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
28 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
29 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
30 internal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0011029
31 polycythemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001901
32 poor appetite 58 31 occasional (7.5%) Occasional (29-5%) HP:0004396
33 anasarca 58 31 occasional (7.5%) Occasional (29-5%) HP:0012050
34 metabolic alkalosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200114
35 hepatic encephalopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002480
36 mood changes 58 31 occasional (7.5%) Occasional (29-5%) HP:0001575
37 hepatic necrosis 58 31 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002605
38 hemobilia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100762
39 pedal edema 31 occasional (7.5%) HP:0010741
40 hypotension 58 31 very rare (1%) Very rare (<4-1%) HP:0002615
41 liver abscess 58 31 very rare (1%) Very rare (<4-1%) HP:0100523
42 budd-chiari syndrome 58 31 very rare (1%) Very rare (<4-1%) HP:0002639
43 vomiting 58 Frequent (79-30%)
44 hepatic fibrosis 58 Very frequent (99-80%)
45 abnormality of the liver 58 Very frequent (99-80%)
46 elevated alpha-fetoprotein 58 Very frequent (99-80%)
47 edema of the lower limbs 58 Occasional (29-5%)
48 hepatocellular carcinoma 31 HP:0001402
49 micronodular cirrhosis 31 HP:0001413
50 constitutional symptom 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM:

56
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM:

114550

UMLS symptoms related to Hepatocellular Carcinoma:


nausea and vomiting, constipation, fever, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.05 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.05 KRAS
3 Decreased viability GR00221-A-1 10.05 FGFR1 HRAS KRAS NRAS PDGFRL PIK3CA
4 Decreased viability GR00221-A-2 10.05 FGFR1 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.05 HRAS NRAS
6 Decreased viability GR00221-A-4 10.05 PIK3CA
7 Decreased viability GR00301-A 10.05 KRAS
8 Decreased viability GR00381-A-1 10.05 KRAS
9 Decreased viability GR00402-S-2 10.05 FGFR1 HRAS KRAS NRAS PDGFRL PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.92 IGF2R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.92 IGF2R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.92 CTNNB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.92 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.92 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.92 IGF2R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.92 PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.92 PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.92 PIK3CA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.92 KRAS
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.92 APC CTNNB1 KRAS PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.92 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.92 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.92 APC
24 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.92 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.92 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.92 APC
27 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.92 IGF2R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.92 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.92 IGF2R
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.92 APC
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.92 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.92 CTNNB1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.92 APC CTNNB1 IGF2R KRAS PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.92 KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.92 PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.92 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.92 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.92 CTNNB1 IGF2R
39 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.92 APC CTNNB1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.92 KRAS
41 Decreased cell migration GR00055-A-1 9.55 CTNNB1 HRAS KRAS MET PIK3CA

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
2 cellular MP:0005384 10.42 APC AXIN1 CASP8 CTNNB1 FGFR1 IGF2R
3 growth/size/body region MP:0005378 10.41 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
4 behavior/neurological MP:0005386 10.4 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
5 embryo MP:0005380 10.36 APC AXIN1 CASP8 CTNNB1 FGFR1 IGF2R
6 homeostasis/metabolism MP:0005376 10.36 APC CASP8 CTNNB1 FGFR1 HRAS IGF2R
7 endocrine/exocrine gland MP:0005379 10.35 APC CASP8 CTNNB1 FGFR1 HRAS IGF2R
8 craniofacial MP:0005382 10.34 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
9 digestive/alimentary MP:0005381 10.33 APC AXIN1 CTNNB1 FGFR1 HRAS KRAS
10 mortality/aging MP:0010768 10.32 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
11 immune system MP:0005387 10.28 APC CASP8 CTNNB1 FGFR1 KRAS MET
12 integument MP:0010771 10.22 APC CASP8 CTNNB1 FGFR1 HRAS KRAS
13 nervous system MP:0003631 10.22 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
14 liver/biliary system MP:0005370 10.19 APC CASP8 CTNNB1 IGF2R KRAS MET
15 neoplasm MP:0002006 10.17 APC CASP8 CTNNB1 HRAS KRAS MET
16 limbs/digits/tail MP:0005371 10.16 APC AXIN1 CTNNB1 FGFR1 IGF2R KRAS
17 normal MP:0002873 10.1 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
18 muscle MP:0005369 10.06 APC CASP8 CTNNB1 FGFR1 KRAS MET
19 hearing/vestibular/ear MP:0005377 10.03 APC AXIN1 CTNNB1 FGFR1 KRAS TP53
20 no phenotypic analysis MP:0003012 9.97 CTNNB1 FGFR1 HRAS KRAS MET NRAS
21 renal/urinary system MP:0005367 9.9 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
22 pigmentation MP:0001186 9.65 APC CTNNB1 KRAS NRAS TP53
23 respiratory system MP:0005388 9.65 AXIN1 CASP8 CTNNB1 HRAS IGF2R KRAS
24 skeleton MP:0005390 9.4 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R

Drugs & Therapeutics for Hepatocellular Carcinoma

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 772)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Tegafur Approved, Investigational Phase 4 17902-23-7 5386
3
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
4
acetic acid Approved Phase 4 64-19-7 176
5
Desflurane Approved Phase 4 57041-67-5 42113
6
Cefazolin Approved Phase 4 25953-19-9 656510 33255
7
Nadolol Approved Phase 4 42200-33-9 39147
8
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Ethanol Approved Phase 4 64-17-5 702
12
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
13
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
14
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
15
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
16
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
17
Colchicine Approved Phase 4 64-86-8 6167 2833
18
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
19
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
20
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
21
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
22
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
23
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
25
Pantoprazole Approved Phase 4 102625-70-7 4679
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
29
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
30
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
31
Povidone Approved Phase 4 9003-39-8
32
Povidone-iodine Approved Phase 4 25655-41-8
33
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
34
Lenograstim Approved, Investigational Phase 4 135968-09-1
35 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
36
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
37
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
38
Norepinephrine Approved Phase 4 51-41-2 439260
39
Acetaminophen Approved Phase 4 103-90-2 1983
40
Propranolol Approved, Investigational Phase 4 525-66-6 4946
41
Nicotine Approved Phase 4 54-11-5 942 89594
42
Methadone Approved Phase 4 76-99-3 4095
43
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
44
Cobicistat Approved Phase 4 1004316-88-4
45
Azathioprine Approved Phase 4 446-86-6 2265
46
Coal tar Approved Phase 4 8007-45-2
47
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
48
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
49
Methyltestosterone Approved Phase 4 58-18-4 6010
50
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0

Interventional clinical trials:

(show top 50) (show all 3088)
# Name Status NCT ID Phase Drugs
1 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
2 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
3 An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
4 Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
5 The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy Unknown status NCT01102335 Phase 4 Telbivudine
6 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
7 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
8 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
9 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
10 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
11 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
12 Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study Unknown status NCT02832882 Phase 4
13 Radiofrequency Ablation Using Dual Cooled-Wet Electrode for Small Hepatocellular Carcinoma With No-touch Technique: Preliminary Study Unknown status NCT02806076 Phase 4
14 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
15 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial Unknown status NCT02399033 Phase 4 Xihuang Capsules
16 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETV;TDF;ADV;Peginterferon Alfa-2a
17 A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma Unknown status NCT01997957 Phase 4 S-1
18 Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China Unknown status NCT02631499 Phase 4 Epirubicin;lipiodol
19 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
20 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
21 A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
22 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
23 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
24 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
25 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
26 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
27 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
28 Improving Cone-beam Computed Tomography for Image Guided Stereotactic Body Radiation Therapy of the Liver Using Gadoxetate Disodium Unknown status NCT03215355 Phase 4 Primovist
29 Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial Unknown status NCT01351194 Phase 4
30 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
31 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
32 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
33 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
34 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
35 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
36 Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
37 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
38 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
39 Cholestatic Drug-induced Liver Injury: Correlation With Genotypes of UGT1A1 and 1A7, and Treatment Effect of Ursodeoxycholic Acid Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
40 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
41 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
42 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
43 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
44 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
45 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
46 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
47 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
48 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
49 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
50 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib
sorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA

Anatomical Context for Hepatocellular Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatocellular Carcinoma:

19
Liver

MalaCards organs/tissues related to Hepatocellular Carcinoma:

40
Liver, T Cells, Lung, Testes, Breast, Bone, Endothelial

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 48390)
# Title Authors PMID Year
1
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 56 6
15608678 2005
2
MicroRNA expression, survival, and response to interferon in liver cancer. 61 46 56
19812400 2009
3
Somatic mutations of the APC gene in sporadic hepatoblastomas. 56 6
8764128 1996
4
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. 54 61 6
10435629 1999
5
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. 61 56
30814741 2019
6
Necroptosis microenvironment directs lineage commitment in liver cancer. 61 56
30209397 2018
7
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 61 56
24578576 2014
8
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
24047069 2013
9
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
24047070 2013
10
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
24047071 2013
11
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
23758232 2013
12
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 61 56
22922871 2012
13
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. 61 56
21822264 2011
14
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. 61 56
21499248 2011
15
Diet-induced hepatocellular carcinoma in genetically predisposed mice. 61 56
19454484 2009
16
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 61 56
19221438 2009
17
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. 61 56
18167406 2008
18
Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. 61 56
12668613 2003
19
Molecular pathogenesis of human hepatocellular carcinoma. 61 56
12149612 2002
20
Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. 54 56
10779553 2000
21
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 54 6
10700176 2000
22
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. 61 56
9589695 1998
23
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. 54 56
7892276 1995
24
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 54 6
1849234 1991
25
Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. 61 56
2573067 1989
26
Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. 61 56
2847975 1988
27
Fraternal hepatocellular carcinoma in young children in two families. 61 56
6321015 1984
28
Familial hepatocellular carcinoma in an endemic area of Thailand. 61 56
6317164 1984
29
Primary hepatocellular carcinoma in three male siblings. 61 56
4298178 1968
30
FRATERNAL PRIMARY HEPATOCELLULAR CARCINOMA IN THREE MALE, ADULT SIBLINGS. 61 56
14320698 1965
31
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. 61 42
31590579 2019
32
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
33
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
34
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
35
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
36
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
37
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. 61 46
20924108 2010
38
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. 61 46
20842113 2010
39
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. 56
20676096 2010
40
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. 61 46
19843643 2010
41
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. 61 46
20041405 2010
42
MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. 61 46
20103675 2010
43
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. 56
19762333 2009
44
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. 61 46
19726678 2009
45
MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. 61 46
19863192 2009
46
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. 61 46
19711427 2009
47
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. 61 46
19617899 2009
48
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 61 46
19671867 2009
49
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. 61 46
19473441 2009
50
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. 61 46
19585654 2009